Noninvasive ventilation (NIV) delivered by helmet (Sea-Long Medical Systems Inc.) significantly reduced the intubation rate compared with NIV delivered through an oronasal face mask in patients with acute respiratory distress syndrome (ARDS).
According to the results from this randomized controlled trial published in JAMA (2016;315:2435-2441), patients who used the helmet also had more ventilator-free days and significantly reduced ICU lengths of stay. The helmet (Figure) was so effective, in fact, that the trial was stopped early by the data and safety monitoring board.
“For patients with ARDS, treatment with helmet NIV was associated with significantly lower intubation rates and lower respiratory rate,” said John P. Kress, MD, of the Department of Medicine, Section of Pulmonary and Critical Care, at the University of Chicago Medicine. “There was also a statistically significant reduction in 90-day mortality with helmet NIV, which was a huge finding.”